Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players (Q38650049)

5 September 2017

Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players (English)

1 reference

5 September 2017

Young R Lee

1

1 reference

5 September 2017

Danni McMahan

series ordinal

2

1 reference

5 September 2017

Catherine McCall

series ordinal

3

1 reference

5 September 2017

Gregory K Perry

series ordinal

4

1 reference

5 September 2017

language of work or name

1 reference

26 November 2015

1 reference

5 September 2017

1 reference

5 September 2017

75

1 reference

5 September 2017

18

1 reference

5 September 2017

2097-2117

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-015-0506-7

5 September 2017

0 references

cites work

Essentials for selecting antimicrobial therapy for intra-abdominal infections

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Increasing prevalence of carbapenem-resistant Enterobacteriaceae and strategies to avert a looming crisis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

2013 WSES guidelines for management of intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Drug therapy: The newer cephalosporins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefuroxime: a review of its antibacterial activity, pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ceftazidime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Amoxicillin/clavulanic acid. An update of its antibacterial activity, pharmacokinetic properties and therapeutic use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Comparative review of the carbapenems

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Retrospective review of neurotoxicity induced by cefepime and ceftazidime

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ceftriaxone. A reappraisal of its antibacterial activity and pharmacokinetic properties, and an update on its therapeutic use with particular reference to once-daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Monotherapy versus multi-drug therapy for the treatment of perforated appendicitis in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Single daily dosing ceftriaxone and metronidazole vs standard triple antibiotic regimen for perforated appendicitis in children: a prospective randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefepime clinical pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefepime: a reappraisal in an era of increasing antimicrobial resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Cefepime neurotoxicity despite renal adjusted dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

The clinical development and launch of amoxicillin/clavulanate for the treatment of a range of community-acquired infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ticarcillin: a review of its pharmacological properties and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Doripenem: a new carbapenem antibiotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

The new fluoroquinolones: A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Glycopeptide antibiotics: back to the future.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Tigecycline: a glycylcycline antimicrobial agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

21 January 2018

Tigecycline: an update

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Metronidazole is still the drug of choice for treatment of anaerobic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ceftazidime-avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Effect of age and sex on the pharmacokinetics and safety of avibactam in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Comparative in vitro and in vivo efficacies of human simulated doses of ceftazidime and ceftazidime-avibactam against Pseudomonas aeruginosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Antimicrobial activity of ceftolozane-tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. Hospitals (2011-2012).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Trial of short-course antimicrobial therapy for intraabdominal infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Can we define the ideal duration of antibiotic therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Consequences of inappropriate initial empiric parenteral antibiotic therapy among patients with community-acquired intra-abdominal infections in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

International study of the prevalence and outcomes of infection in intensive care units

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Pharmacokinetic issues for antibiotics in the critically ill patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Pharmacokinetics of beta-lactam antibiotics in patients with intra-abdominal disease: a structured review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Pharmacokinetics of meropenem in patients with intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

A focus on intra-abdominal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Moxifloxacin: a respiratory fluoroquinolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

Pharmacokinetics of Meropenem Determined by Microdialysis in the Peritoneal Fluid of Patients With Severe Peritonitis Associated With Septic Shock

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0506-7

National Hospital Discharge Survey: 2007 summary.

21 January 2018

1 reference

12 December 2020

Safety of ceftriaxone sodium at extremes of age

1 reference

12 December 2020

Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

1 reference

12 December 2020

Intra-abdominal Infections

1 reference

12 December 2020

Metronidazole. A therapeutic review and update

1 reference

12 December 2020

A reassessment of ticarcillin/clavulanic acid dose recommendations for infants, children and adults

1 reference

12 December 2020

Economic consequences of failure of initial antibiotic therapy in hospitalized adults with complicated intra-abdominal infections

1 reference

12 December 2020

1 reference

12 December 2020

Canadian practice guidelines for surgical intra-abdominal infections

1 reference

12 December 2020

Piperacillin-Tazobactam: a new beta-lactam-beta-lactamase inhibitor combination

1 reference

12 December 2020

10.1007/S40265-015-0506-7

Identifiers

DOI

1 reference

Dimensions Publication ID

5 September 2017

1023693416

0 references

Fatcat ID

release_foze2vclrzfzpgf2w6d66r6hqi

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/foze2vclrzfzpgf2w6d66r6hqi

24 November 2022

mapped directly with Wikidata item

1 reference